Results 171 to 180 of about 1,334,045 (336)
Funnel plots for comparing provider performance based on patient-reported outcome measures [PDF]
, 2011 Jenny Neuburger +4 more
openalex +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Turkish Journal of Vascular SurgeryPelvic venous disorders (PeVD) present with a range of heterogenous symptoms that arise from altered venous hemodynamics in the pelvis. Many of these symptoms lead to mental health and quality of life issues and are not limited to the pelvic region.
Sriram Narayanan
doaj
Development of a patient-reported outcome measure in adult cystic fibrosis
, 2008 Sam Salek, Lauren Corke, R.I. Ketchell
openalex +1 more source
PRM66 Comparison of Reconciliation and Review Methodologies for the Translation of Patient Reported Outcome (PRO) Measures [PDF]
, 2011 A. Verjee-Lorenz +3 more
openalex +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA [PDF]
, 2011 Brooke Dennee-Sommers +5 more
openalex +1 more source
Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance [PDF]
, 2013 core +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source